Evidence map›Paper›PMID 36674919›Full record

ArticleInternational journal of molecular sciences2023

Concern about the Effectiveness of mRNA Vaccination Technology and Its Long-Term Safety: Potential Interference on miRNA Machinery.

Gianmarco Stati, Paolo Amerio, Mario Nubile, Silvia Sancilio, Francesco Rossi, Roberta Di Pietro

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Gianmarco StatiDepartment of Medicine and Ageing Sciences, G. d'Annunzio University of Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy.ORCID 0000-0002-9189-5932
Paolo AmerioDepartment of Medicine and Ageing Sciences, G. d'Annunzio University of Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy.ORCID 0000-0003-1589-9672
Mario NubileOphthalmology Clinic, National Centre of High Technology (CNAT) in Ophthalmology, G. d'Annunzio University of Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy.
Silvia SancilioDepartment of Medicine and Ageing Sciences, G. d'Annunzio University of Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy.ORCID 0000-0003-2173-943X
Francesco RossiDepartment of Molecular Sciences and Nanosystems, Ca' Foscari University, Via Torino, 155/b, 30170 Venice, Italy.ORCID 0000-0001-6135-6615
Roberta Di PietroDepartment of Medicine and Ageing Sciences, G. d'Annunzio University of Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy.ORCID 0000-0002-0709-6901
University of Chieti-Pescara · ITCa' Foscari University of Venice · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After the outbreak of the pandemic due to COVID-19 infection, several vaccines were developed on short timelines to counteract the public health crisis. To allow the administration of mRNA vaccines through a faster-paced approval process, the Emergency Use Authorization (EUA) was applied. The Ba.5 (omicron) variant of SARS-CoV-2 is the predominant one at this moment. Its highly mutable single-stranded RNA genome, along with its high transmissivity, generated concern about the effectiveness of vaccination. The interaction between the vaccine and the host cell is finely regulated by miRNA machinery, a complex network that oversees a wide range of biological processes. The dysregulation of miRNA machinery has been associated with the development of clinical complications during COVID-19 infection and, moreover, to several human pathologies, among which is cancer disease. Now that in some areas, four doses of mRNA vaccine have been administered, it is natural to wonder about its effectiveness and long-term safety.

Indexed as

COVID-19MicroRNAsHumansRNA, MessengerSARS-CoV-2TechnologyVaccinationMicroRNAsRNA, MessengerBNT162b2cancerCOVID-19innovative formulationmiRNAsmRNA1273mRNA vaccinesSARS-CoV-2

Identifiers

PMID36674919
PMCPMC9863643
OpenAlexW4315649162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.